Patent ID: 9670286
Date: 2017-06-06
CPC Classifications: A61K,C07K

Claim:
1. A method of inducing an immune response to a Trop-2 expressing cancer comprising: a) administering to a subject with a Trop-2 expressing cancer a bispecific antibody that comprises (i) at least one anti-Trop-2 antibody or antigen-binding fragment thereof and one anti-CD3 antibody or antigen-binding fragment thereof, wherein the at least one anti-Trop-2 antibody or fragment thereof binds to the same epitope as an anti-Trop-2 antibody comprising the light chain CDR sequences CDR1 (KASQDVSIAVA, SEQ ID NO:115); CDR2 (SASYRYT, SEQ ID NO:116); and CDR3 (QQHYITPLT, SEQ ID NO:117) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:118); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:119) and CDR3 (GGFGSSYWYFDV, SEQ ID NO:120); and b) administering to the subject at least one therapeutic agent selected from the group consisting of (i) interferon α; and (ii) a checkpoint inhibitor antibody.